Recordati SpA's EBIT per Share for the
three
months ended in Mar. 2026 was €1.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €3.42.
During the past 12 months, the average EBIT per Share Growth Rate of Recordati SpA was 13.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 13.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 9.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 8.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Recordati SpA's EBIT per Share or its related term are showing as below:
MIL:REC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 1.7 Med: 10.8 Max: 20.3
Current: 13.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Recordati SpA was 20.30% per year. The lowest was 1.70% per year. And the median was 10.80% per year.
MIL:REC's 3-Year EBIT Growth Rate is ranked better than 58.64% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs MIL:REC: 13.30
Recordati SpA's EBIT for the
three
months ended in Mar. 2026 was €225 Mil.
Recordati SpA (MIL:REC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Recordati SpA EBIT per Share Related Terms
Recordati SpA EBIT per Share Historical Data
* Premium members only.
The historical data trend for Recordati SpA's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA (MIL:REC) has a EBIT per Share of €3.42 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Recordati SpA and its competitors. According to the industry distribution chart, Recordati SpA ranks #335 out of 810 companies in the Drug Manufacturers industry, placing it in the top 41.4%.
Is Recordati SpA's EBIT per Share too high?
Recordati SpA's current EBIT per Share is €3.42. Based on the distribution chart, Recordati SpA ranks #335 out of 810 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Recordati SpA has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #335 out of 810 companies for EBIT per Share. This puts Recordati SpA in the upper half of its industry. The industry median EBIT per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current EBIT per Share is €3.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.71, compared to a current price of €51.30 — trading 15.5% below its estimated fair value. The current EBIT per Share is €3.42. Recordati SpA's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current EBIT per Share is €3.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.30 is trading 15.5% below its estimated GF Value™ of €60.71.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
EBIT per Share: €3.42
GF Value™: €60.71 vs. price of €51.30 (15.5% below fair value)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
96GF Score
Get the complete analysis for MIL:REC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
